Results 221 to 230 of about 416,899 (328)

Intron mis-splicing: no alternative? [PDF]

open access: bronze, 2008
Scott William Roy, Manuel Irimia
openalex   +1 more source

Pathogenesis and potential therapeutic targets of trichorhinophalangeal syndrome; lessons obtained from animal studies

open access: yesDevelopmental Dynamics, EarlyView.
Abstract Trichorhinophalangeal syndrome (TRPS) is a rare genetic disease inherited in an autosomal dominant manner. It occurs in 1 in 100,000 people globally and is caused by several types of mutations of the TRPS1 gene. Since the first human patient was reported in 1966, typical and atypical pathologies, disease courses, and treatment case ...
Naoya Saeki   +6 more
wiley   +1 more source

Abnormal Splicing in the Final Intron of PRX Results in Dominant Congenital Cataract Without Neurological Phenotype. [PDF]

open access: yesInvest Ophthalmol Vis Sci
Reis LM   +9 more
europepmc   +1 more source

A pilot study on DNA methylation changes for non‐invasive molecular diagnostics in heart failure

open access: yesESC Heart Failure, EarlyView.
A liquid biopsy approach integrating the high‐resolution RRBS DNA methylation platform and network‐oriented strategy identified the hypomethylation of CPTA1, CKAP4, SPTB, SYT6, EIF2S2, and RAB11FIP1 genes as useful biomarkers in distinguishing between ischaemic and non‐ischaemic HF aetiologies.
Giuditta Benincasa   +7 more
wiley   +1 more source

Dynamic assembly of a large multidomain ribozyme visualized by cryo-electron microscopy. [PDF]

open access: yesNat Commun
Jadhav S   +9 more
europepmc   +1 more source

THE EFFECT OF MONOCOT INTRONS ON TRANSGENE EXPRESSION IN Nicotiana GENUS PLANTS [PDF]

open access: diamond, 2018
I. O. Nitovska   +2 more
openalex   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

open access: yesEnvironmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons   +17 more
wiley   +1 more source

Corrigendum: Novel Genomic and Evolutionary Perspective of Cyanobacterial tRNAs

open access: yesFrontiers in Genetics, 2020
Tapan K. Mohanta   +3 more
doaj   +1 more source

UCP3 gene variants and obesity in a Pakistani sample population. [PDF]

open access: yesSci Rep
Bhatti AA   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy